Springer Healthcare Announces Agreement With ASCO®

Springer Healthcare, part of Springer Science+Business Media, has signed an extensive three-year reprints and sales agreement effective 1 January 2012 with the American Society of Clinical Oncology® (ASCO), the world's leading professional organization representing physicians who care for people with cancer.

"Springer Healthcare is a leader in global licensing sales and has a track record of producing materials that are of high quality and value," said Dr. Allen Lichter, Chief Executive Officer of ASCO. "We are looking forward to working with Springer Healthcare to further the reach of many of ASCO's educational resources, including our flagship journal, the Journal of Clinical Oncology and our practice management journal, the Journal of Oncology Practice."

Springer Healthcare will be the exclusive supplier of reprints from articles published in ASCO's Journal of Clinical Oncology and Journal of Oncology Practice for North and South America, most of Europe, India, and other territories. In addition, Springer Healthcare will be the exclusive representative for licensing of other ASCO educational resources including the ASCO Annual Meeting abstracts and Educational Book, Virtual Meeting content, symposia proceedings, patient materials, and ASCO University® - the Society's online learning environment.

Steve Entwistle, Vice President of Springer Healthcare, commented, "We are honored to be appointed by ASCO to represent their journal reprints business as well as their other prestigious content. We value our relationship with ASCO, and we appreciate the confidence that they are showing in us."

About Springer Healthcare
Springer Healthcare is a leading publisher of medical educational products and forms part of Springer Science+Business Media. Springer Healthcare has undergone significant growth in the past decade and has expanded rapidly, with global reach into all international markets and more than 150 employees worldwide. Springer Healthcare's focus is on meeting the communication and publishing needs of the international healthcare communities, with a growing portfolio of products, including MedWire News, strategic consultancy, event management, eBusiness products and services, as well as print and digital medical publishing.

About Springer Science+Business Media
Springer Science+Business Media is a leading global scientific publisher, delivering quality content through innovative information products and services. The company is also a trusted provider of local-language professional publications in Europe, especially in Germany and the Netherlands. In the science, technology and medicine (STM) sector, the group publishes about 2,000 journals and more than 7,000 new books per year, as well as the largest STM eBook Collection worldwide. Springer has operations in about 20 countries in Europe, the USA, and Asia, and has more than 5,500 employees. In 2010, it generated annual sales of approximately EUR 866 million.

Most Popular Now

Pfizer's elranatamab granted FDA Breakthrough Ther…

Pfizer Inc. (NYSE:PFE) announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administrati...

Vividion Therapeutics names Jenna Goldberg as Chie…

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision the...

Bayer with continued strong performance

The Bayer Group maintained its strong business performance across all three divisions in the third quarter. "Despite rising inflation and global supply chain problems, we...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY® Original/Omicron ...

Sanofi and GSK's next-generation COVID-19 booster …

After the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for VidPrevtyn® Beta, the vaccine was approved by t...

Sugar molecules as a target in cancer therapy

Cancer cells use sugar molecules on their surface to disable attacks by the body's immune system. Researchers at the University of Basel now report on how this mechanism ...

COVID vaccination improves effectiveness of cancer…

Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. Until now, it was feared that vaccination against Co...

Making melanoma immortal: Pitt scientists discover…

Scientists at the University of Pittsburgh School of Medicine have discovered the missing puzzle piece in the mystery of how melanoma tumors control their mortality. I...

GSK announces positive Phase IIa study results for…

GSK plc (LSE/NYSE: GSK) announced positive results from a Phase IIa study demonstrating that GSK3036656, a first-in-class investigational antitubercular agent, was well t...

New drug shows promise for fighting both COVID-19 …

While vaccination can provide life-saving protection against COVID-19, scientists are still searching for ways to treat severe infections, including in people who cannot ...

Machine learning can help predict patient response…

Predicting which patients will respond well to treatment is a quandary that has plagued the field of cancer immunotherapy for more than four decades. Now, researchers at ...

Study reveals vaccine confidence declined consider…

A new study suggests that, despite the success of the COVID-19 vaccination campaigns, vaccine confidence has declined significantly since the start of the pandemic. Re...